Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Aug 21:7:177.
doi: 10.3389/fonc.2017.00177. eCollection 2017.

Radiation Treatment in Women with Ovarian Cancer: Past, Present, and Future

Affiliations
Review

Radiation Treatment in Women with Ovarian Cancer: Past, Present, and Future

Emma C Fields et al. Front Oncol. .

Abstract

Ovarian cancer is the most lethal of the gynecologic cancers, with 5-year survival rates less than 50%. Most women present with advanced stage disease as the pattern of spread is typically with dissemination of malignancy throughout the peritoneal cavity prior to development of any symptoms. Prior to the advent of platinum-based chemotherapy, radiotherapy was used as adjuvant therapy to sterilize micrometastatic disease. The evolution of radiotherapy is detailed in this review, which establishes radiotherapy as an effective therapy for women with micrometastatic disease in the peritoneal cavity after surgery, ovarian clear cell carcinoma, focal metastatic disease, and for palliation of advanced disease. However, with older techniques, the toxicity of whole abdominal radiotherapy and the advancement of systemic therapies have limited the use of radiotherapy in this disease. With newer radiotherapy techniques, including intensity-modulated radiotherapy (IMRT), stereotactic body radiotherapy (SBRT), and low-dose hyperfractionation in combination with targeted agents, radiotherapy could be reconsidered as part of the standard management for this deadly disease.

Keywords: abscopal effect; novel therapeutics; ovarian cancer; poly(ADP-ribose) polymerase inhibitors; radiation.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Techniques for treating whole abdominal radiation. (A) Open field technique AP beam. (B) Open field technique PA beam with kidney blocks.
Figure 2
Figure 2
Stereotactic body radiotherapy (SBRT) plan for the treatment of a para-aortic lymph node for a woman with recurrent serous ovarian cancer. The plan is shown in axial, sagittal, and coronal orientations. The planning target volume is color washed in green, the kidneys are yellow, and blue and the bowel is orange. The dose is 30 Gy and prescribed in five fractions.
Figure 3
Figure 3
Dosimetric comparisons of three dimensional conformal and intensity modulation radiation therapy (IMRT) plans for whole abdominal radiotherapy. The plans are each shown in axial, sagittal, and coronal orientations and the dose volume histogram comparison is below. The planning target volume (whole abdominal cavity) is red, liver is yellow, kidneys are green, and bone marrow is brown. The IMRT plan is the dashed lines and the 3DCRT plan DVH’s are solid.

References

    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin (2017) 67(1):7–30.10.3322/caac.21387 - DOI - PubMed
    1. Kurman RJ, Shih Ie M. Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer – shifting the paradigm. Hum Pathol (2011) 42(7):918–31.10.1016/j.humpath.2011.03.003 - DOI - PMC - PubMed
    1. Jarboe EA, Folkins AK, Drapkin R, Ince TA, Agoston ES, Crum CP. Tubal and ovarian pathways to pelvic epithelial cancer: a pathological perspective. Histopathology (2009) 55(5):619.10.1111/j.1365-2559.2009.03408.x - DOI - PubMed
    1. Steffensen KD, Waldstrom M, Grove A, Lund B, Pallisgard N, Jakobsen A. Improved classification of epithelial ovarian cancer: results of 3 Danish cohorts. Int J Gynecol Cancer (2011) 21(9):1592–600.10.1097/IGC.0b013e31822a0f6b - DOI - PubMed
    1. Kurman RJ, Shih Ie M. The dualistic model of ovarian carcinogenesis: revisited, revised, and expanded. Am J Pathol (2016) 186(4):733–47.10.1016/j.ajpath.2015.11.011 - DOI - PMC - PubMed